📊 PVLA Key Takeaways
Is Palvella Therapeutics, Inc.. (PVLA) a Good Investment?
Palvella Therapeutics exhibits fortress-like financial health with $206.4M cash, minimal debt, and exceptional liquidity (28.88x current ratio), providing substantial runway despite -$10.9M annual operating cash burn. The company demonstrates strong early commercialization momentum with 303% YoY revenue growth, but remains deeply unprofitable with -$15.8M net losses and negative operating margins exceeding -1380%, reflecting typical pre-profitability pharmaceutical dynamics with uncertain path to viability.
Palvella Therapeutics, Inc.. Key Strengths (PVLA)
- Exceptional balance sheet with $206.4M cash and zero long-term debt provides ~19+ years of runway at current burn rate
- Robust early-stage revenue growth of 303.4% YoY suggests successful product commercialization initiation
- Outstanding liquidity metrics (28.88x current and quick ratios) eliminate near-term solvency risk and provide operational flexibility
PVLA Stock Risks: Palvella Therapeutics, Inc.. Investment Risks
- Company is unprofitable with operating losses of -$14.9M and net losses of -$15.8M against only $1.1M revenue, indicating severe business scale challenges
- Negative operating cash flow of -$10.9M demonstrates the company is consuming cash reserves without operational self-sufficiency
- Pre-revenue stage pharmaceutical company faces binary outcome risk: revenue scaling and pathway to profitability success versus funding exhaustion or market adoption failure
Key Metrics to Watch
- Revenue growth trajectory and absolute revenue scale (ability to sustain 300%+ growth and reach meaningful commercial thresholds)
- Operating cash flow burn rate and timeline to operating cash flow positive
- Cash runway remaining and capital efficiency improvements as company scales operations
Palvella Therapeutics, Inc.. (PVLA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 28.88x current ratio provides a solid financial cushion.
PVLA Profit Margin, ROE & Profitability Analysis
PVLA vs Healthcare Sector: How Palvella Therapeutics, Inc.. Compares
How Palvella Therapeutics, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Palvella Therapeutics, Inc.. Stock Overvalued? PVLA Valuation Analysis 2026
Based on fundamental analysis, Palvella Therapeutics, Inc.. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Palvella Therapeutics, Inc.. Balance Sheet: PVLA Debt, Cash & Liquidity
PVLA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Palvella Therapeutics, Inc..'s revenue has declined by 11% over the 5-year period, indicating business contraction. The most recent EPS of $-7.83 indicates the company is currently unprofitable.
PVLA Revenue Growth, EPS Growth & YoY Performance
PVLA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$2.9M | $-2.19 |
| Q2 2024 | N/A | -$3.6M | $-2.76 |
| Q1 2024 | $6.0K | -$4.9M | N/A |
| Q3 2023 | $5.1M | -$9.7M | N/A |
| Q2 2023 | $3.5M | $4.0M | $0.05 |
| Q1 2023 | $2.0M | -$5.1M | N/A |
| Q3 2022 | $2.8M | -$9.7M | N/A |
| Q2 2022 | $2.5M | -$10.3M | $-0.14 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Palvella Therapeutics, Inc.. Dividends, Buybacks & Capital Allocation
PVLA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Palvella Therapeutics, Inc.. (CIK: 0001583648)
📋 Recent SEC Filings
❓ Frequently Asked Questions about PVLA
What is the AI rating for PVLA?
Palvella Therapeutics, Inc.. (PVLA) has an AI grade of B with 55% confidence, based on fundamental analysis of SEC EDGAR filings.
What are PVLA's key strengths?
Claude: Exceptional balance sheet with $206.4M cash and zero long-term debt provides ~19+ years of runway at current burn rate. Robust early-stage revenue growth of 303.4% YoY suggests successful product commercialization initiation.
What are the risks of investing in PVLA?
Claude: Company is unprofitable with operating losses of -$14.9M and net losses of -$15.8M against only $1.1M revenue, indicating severe business scale challenges. Negative operating cash flow of -$10.9M demonstrates the company is consuming cash reserves without operational self-sufficiency.
What is PVLA's revenue and growth?
Palvella Therapeutics, Inc.. reported revenue of $1.1M.
Does PVLA pay dividends?
Palvella Therapeutics, Inc.. does not currently pay dividends.
Where can I find PVLA SEC filings?
Official SEC filings for Palvella Therapeutics, Inc.. (CIK: 0001583648) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is PVLA's EPS?
Palvella Therapeutics, Inc.. has a diluted EPS of $-1.20.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is PVLA's fundamental grade?
Based on our AI fundamental analysis in June 2026, Palvella Therapeutics, Inc.. has a B grade with 55% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is PVLA stock overvalued or undervalued?
Valuation metrics for PVLA: ROE of -6.8% (sector avg: 15%), net margin of -1,469.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is PVLA's AI grade for 2026?
Our dual AI analysis gives Palvella Therapeutics, Inc.. a combined B grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is PVLA's free cash flow?
Palvella Therapeutics, Inc..'s operating cash flow is $-10.9M, with capital expenditures of $0.0. FCF margin is -1,012.5%.
How does PVLA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,469.4% (avg: 12%), ROE -6.8% (avg: 15%), current ratio 28.88 (avg: 2).